Knockdown of AQP5 activated the MAPK signaling pathway, reducing cell invasiveness and proliferation, and enhanced the chemosensitivity of breast cancer cells, suggesting AQP5 is of interest as a biomarker and a pharmacological target [178,179]. This evidence concerns the gene AQP5 and breast carcinoma.